Rahul Sharma (Editor)

Nadroparin calcium

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Trade names
  
Fraxiparine, Fraxodi

Bioavailability
  
89% (SC dose)

ATC code
  
B01AB06 (WHO)

Molar mass
  
591.45 g/mol

Nadroparin calcium thuocaznetwpcontentuploads201502Nadroparin

AHFS/Drugs.com
  
International Drug Names

Routes ofadministration
  
SC (except for haemodialysis)

Legal status
  
AU: S4 (Prescription only)CA: ℞-only

Nadroparin (trade name, Fraxiparine or Fraxodi) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by sanofi-synthelabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the stomach. Injections are given once or twice daily depending on the condition.

References

Nadroparin calcium Wikipedia